Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens.

Fernandez-Pol S, van de Rijn M, Natkunam Y, Charville GW.

Virchows Arch. 2018 Jul 17. doi: 10.1007/s00428-018-2410-5. [Epub ahead of print]

PMID:
30014288
2.

PAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation.

Charville GW, Wang WL, Ingram DR, Roy A, Thomas D, Patel RM, Hornick JL, van de Rijn M, Lazar AJ.

Mod Pathol. 2018 Jul 9. doi: 10.1038/s41379-018-0095-6. [Epub ahead of print] No abstract available.

PMID:
29985454
3.

Tissue-Specific Expression of the Low-Affinity IgG Receptor, FcγRIIb, on Human Mast Cells.

Burton OT, Epp A, Fanny ME, Miller SJ, Stranks AJ, Teague JE, Clark RA, van de Rijn M, Oettgen HC.

Front Immunol. 2018 Jun 6;9:1244. doi: 10.3389/fimmu.2018.01244. eCollection 2018.

4.

GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma.

Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager JB, Ayers K, Bakr S, Gentles AJ, Diehn M, Quon A, West RB, Nair V, van de Rijn M, Napel S, Plevritis SK.

Cancer Res. 2018 Jul 1;78(13):3445-3457. doi: 10.1158/0008-5472.CAN-17-2928. Epub 2018 May 14.

PMID:
29760045
5.

Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.

Przybyl J, Kidzinski L, Hastie T, Debiec-Rychter M, Nusse R, van de Rijn M.

Gynecol Oncol. 2018 May;149(2):388-393. doi: 10.1016/j.ygyno.2018.03.007. Epub 2018 Mar 12.

PMID:
29544705
6.

Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma.

Hayes MN, McCarthy K, Jin A, Oliveira ML, Iyer S, Garcia SP, Sindiri S, Gryder B, Motala Z, Nielsen GP, Borg JP, van de Rijn M, Malkin D, Khan J, Ignatius MS, Langenau DM.

Cell Stem Cell. 2018 Mar 1;22(3):414-427.e6. doi: 10.1016/j.stem.2018.02.002.

PMID:
29499154
7.

Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.

Przybyl J, Chabon JJ, Spans L, Ganjoo KN, Vennam S, Newman AM, Forgó E, Varma S, Zhu S, Debiec-Rychter M, Alizadeh AA, Diehn M, van de Rijn M.

Clin Cancer Res. 2018 Jun 1;24(11):2688-2699. doi: 10.1158/1078-0432.CCR-17-3704. Epub 2018 Feb 20.

PMID:
29463554
8.

Experience with telemedicine in a multi-disciplinary ALS clinic.

Van De Rijn M, Paganoni S, Levine-Weinberg M, Campbell K, Swartz Ellrodt A, Estrada J, Cohen AB, Schwamm LH, Berry JD.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):143-148. doi: 10.1080/21678421.2017.1392577. Epub 2017 Dec 18.

PMID:
29250986
9.

Implementation of a Multifaceted Interactive Electrodiagnostic Medicine Workshop in a Physical Medicine and Rehabilitation Residency Program.

Donovan J, van de Rijn M, McCabe EL, Shih S, Paganoni S.

Am J Phys Med Rehabil. 2018 Feb;97(2):134-140. doi: 10.1097/PHM.0000000000000828.

PMID:
28953032
10.

EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma.

Charville GW, Wang WL, Ingram DR, Roy A, Thomas D, Patel RM, Hornick JL, van de Rijn M, Lazar AJ.

Mod Pathol. 2017 Sep;30(9):1312-1320. doi: 10.1038/modpathol.2017.49. Epub 2017 Jun 23.

PMID:
28643791
11.

Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.

Przybyl J, Kowalewska M, Quattrone A, Dewaele B, Vanspauwen V, Varma S, Vennam S, Newman AM, Swierniak M, Bakuła-Zalewska E, Siedlecki JA, Bidzinski M, Cools J, van de Rijn M, Debiec-Rychter M.

JCI Insight. 2017 Jun 2;2(11). pii: 94033. doi: 10.1172/jci.insight.94033. [Epub ahead of print]

12.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

13.

Mapping a multiplexed zoo of mRNA expression.

Choi HM, Calvert CR, Husain N, Huss D, Barsi JC, Deverman BE, Hunter RC, Kato M, Lee SM, Abelin AC, Rosenthal AZ, Akbari OS, Li Y, Hay BA, Sternberg PW, Patterson PH, Davidson EH, Mazmanian SK, Prober DA, van de Rijn M, Leadbetter JR, Newman DK, Readhead C, Bronner ME, Wold B, Lansford R, Sauka-Spengler T, Fraser SE, Pierce NA.

Development. 2016 Oct 1;143(19):3632-3637.

14.

Poster 81 Heart of the Matter. Atypical Mechanisms of Amputation in Young Adults. A Review of Two Case Reports.

van de Rijn M, Polich G, Crandell D.

PM R. 2016 Sep;8(9S):S187-S188. doi: 10.1016/j.pmrj.2016.07.124. Epub 2016 Sep 24. No abstract available.

PMID:
27672847
15.

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV.

Mod Pathol. 2016 Sep;29(9):1113. doi: 10.1038/modpathol.2016.103. No abstract available.

16.

PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms.

Charville GW, Varma S, Forgó E, Dumont SN, Zambrano E, Trent JC, Lazar AJ, van de Rijn M.

Am J Surg Pathol. 2016 Oct;40(10):1305-15. doi: 10.1097/PAS.0000000000000717.

PMID:
27526298
17.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

18.

Giant Pulmonary Artery Aneurysm in a Patient With Marfan Syndrome and Pulmonary Hypertension.

Chiu P, Irons M, van de Rijn M, Liang DH, Miller DC.

Circulation. 2016 Mar 22;133(12):1218-21. doi: 10.1161/CIRCULATIONAHA.115.020537. No abstract available.

19.

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV.

Mod Pathol. 2016 Jun;29(6):582-90. doi: 10.1038/modpathol.2016.45. Epub 2016 Mar 18. Erratum in: Mod Pathol. 2016 Sep;29(9):1113.

20.

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.

N Engl J Med. 2016 Jan 21;374(3):211-22. doi: 10.1056/NEJMoa1506597.

21.

Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy.

Casey DL, van de Rijn M, Riley G, Tung KW, Mohler DG, Donaldson SS.

Hand (N Y). 2015 Dec;10(4):602-6. doi: 10.1007/s11552-015-9760-0. Epub 2015 Apr 17. Review.

22.

Molecular subtyping of leiomyosarcoma with 3' end RNA sequencing.

Guo X, Forgó E, van de Rijn M.

Genom Data. 2015 Sep 1;5:366-367.

23.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.

24.

KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.

Chen EC, Karl TA, Kalisky T, Gupta SK, O'Brien CA, Longacre TA, van de Rijn M, Quake SR, Clarke MF, Rothenberg ME.

Gastroenterology. 2015 Sep;149(3):705-17.e2. doi: 10.1053/j.gastro.2015.05.042. Epub 2015 May 28.

25.

Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?

Worhunsky DJ, Gupta M, Gholami S, Tran TB, Ganjoo KN, van de Rijn M, Visser BC, Norton JA, Poultsides GA.

J Surg Oncol. 2015 Jun;111(7):808-12. doi: 10.1002/jso.23904.

PMID:
25920434
26.

Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Guo X, Jo VY, Mills AM, Zhu SX, Lee CH, Espinosa I, Nucci MR, Varma S, Forgó E, Hastie T, Anderson S, Ganjoo K, Beck AH, West RB, Fletcher CD, van de Rijn M.

Clin Cancer Res. 2015 Aug 1;21(15):3501-11. doi: 10.1158/1078-0432.CCR-14-3141. Epub 2015 Apr 20.

27.

A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis.

Scheeren FA, Kuo AH, van Weele LJ, Cai S, Glykofridis I, Sikandar SS, Zabala M, Qian D, Lam JS, Johnston D, Volkmer JP, Sahoo D, van de Rijn M, Dirbas FM, Somlo G, Kalisky T, Rothenberg ME, Quake SR, Clarke MF.

Nat Cell Biol. 2014 Dec;16(12):1238-48. doi: 10.1038/ncb3058. Epub 2014 Nov 2.

PMID:
25362351
28.

Endoscopic molecular imaging of human bladder cancer using a CD47 antibody.

Pan Y, Volkmer JP, Mach KE, Rouse RV, Liu JJ, Sahoo D, Chang TC, Metzner TJ, Kang L, van de Rijn M, Skinner EC, Gambhir SS, Weissman IL, Liao JC.

Sci Transl Med. 2014 Oct 29;6(260):260ra148. doi: 10.1126/scitranslmed.3009457. Epub 2014 Oct 29.

29.

A role for versican in the development of leiomyosarcoma.

Keire PA, Bressler SL, Lemire JM, Edris B, Rubin BP, Rahmani M, McManus BM, van de Rijn M, Wight TN.

J Biol Chem. 2014 Dec 5;289(49):34089-103. doi: 10.1074/jbc.M114.607168. Epub 2014 Oct 15.

30.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

31.

Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.

Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ.

Histopathology. 2015 Apr;66(5):627-38. doi: 10.1111/his.12466. Epub 2015 Jan 12.

32.

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA.

Nat Genet. 2014 Jun;46(6):601-6. doi: 10.1038/ng.2974. Epub 2014 May 4.

33.

Stromal responses among carcinomas--response.

West RB, van de Rijn M, Chen JL.

Clin Cancer Res. 2014 Mar 1;20(5):1397. doi: 10.1158/1078-0432.CCR-13-3238. No abstract available.

34.

Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.

Guo X, Zhu SX, Brunner AL, van de Rijn M, West RB.

Breast Cancer Res. 2013 Dec 17;15(6):R117. doi: 10.1186/bcr3586.

35.

Stromal signatures in endometrioid endometrial carcinomas.

Espinosa I, Catasus L, D' Angelo E, Mozos A, Pedrola N, Bértolo C, Ferrer I, Zannoni GF, West RB, van de Rijn M, Matias-Guiu X, Prat J.

Mod Pathol. 2014 Apr;27(4):631-9. doi: 10.1038/modpathol.2013.131. Epub 2013 Nov 22.

36.

Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities.

van de Rijn M, Guo X, Sweeney RT, Beck AH, West RB.

Histopathology. 2014 Jan;64(1):163-70. doi: 10.1111/his.12290. Epub 2013 Nov 25. Review.

37.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Edris B, Willingham S, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Weissman IL, van de Rijn M.

Oncoimmunology. 2013 Jun 1;2(6):e24452. Epub 2013 May 14.

38.

Stromal responses among common carcinomas correlated with clinicopathologic features.

Chen JL, Espinosa I, Lin AY, Liao OY, van de Rijn M, West RB.

Clin Cancer Res. 2013 Sep 15;19(18):5127-35. doi: 10.1158/1078-0432.CCR-12-3127. Epub 2013 Jun 26.

39.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC.

Science. 2013 Jul 5;341(6141):88-91. doi: 10.1126/science.1238856. Epub 2013 May 30.

40.

Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST].

Kelly L, Bryan K, Kim SY, Janeway KA, Killian JK, Schildhaus HU, Miettinen M, Helman L, Meltzer PS, van de Rijn M, Debiec-Rychter M, O'Sullivan M; NIH Pediatric and Wild-Type GIST Clinic.

PLoS One. 2013 May 24;8(5):e64102. doi: 10.1371/journal.pone.0064102. Print 2013.

41.

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.

Giacomini CP, Sun S, Varma S, Shain AH, Giacomini MM, Balagtas J, Sweeney RT, Lai E, Del Vecchio CA, Forster AD, Clarke N, Montgomery KD, Zhu S, Wong AJ, van de Rijn M, West RB, Pollack JR.

PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.

42.

Desktop transcriptome sequencing from archival tissue to identify clinically relevant translocations.

Sweeney RT, Zhang B, Zhu SX, Varma S, Smith KS, Montgomery SB, van de Rijn M, Zehnder J, West RB.

Am J Surg Pathol. 2013 Jun;37(6):796-803. doi: 10.1097/PAS.0b013e31827ad9b2.

43.

Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics.

Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR.

Cancer Cell. 2013 Feb 11;23(2):215-27. doi: 10.1016/j.ccr.2012.12.019.

44.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4.

45.

Flipping the script on macrophages in leiomyosarcoma.

Edris B, Weiskopf K, Weissman IL, van de Rijn M.

Oncoimmunology. 2012 Oct 1;1(7):1202-1204.

46.

CDX2 is an amplified lineage-survival oncogene in colorectal cancer.

Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3196-205. doi: 10.1073/pnas.1206004109. Epub 2012 Oct 29.

47.

Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement.

Lee CH, Ali RH, Rouzbahman M, Marino-Enriquez A, Zhu M, Guo X, Brunner AL, Chiang S, Leung S, Nelnyk N, Huntsman DG, Blake Gilks C, Nielsen TO, Dal Cin P, van de Rijn M, Oliva E, Fletcher JA, Nucci MR.

Am J Surg Pathol. 2012 Oct;36(10):1562-70.

48.

Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers.

Brunner AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R, Montgomery K, Varma S, Gilks T, Guo X, Foley JW, Witten DM, Giacomini CP, Flynn RA, Pollack JR, Tibshirani R, Chang HY, van de Rijn M, West RB.

Genome Biol. 2012 Aug 28;13(8):R75. doi: 10.1186/gb-2012-13-8-r75.

49.

Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma.

Edris B, Fletcher JA, West RB, van de Rijn M, Beck AH.

Sarcoma. 2012;2012:805614. doi: 10.1155/2012/805614. Epub 2012 Aug 5.

50.

Sox10 and S100 in the diagnosis of soft-tissue neoplasms.

Karamchandani JR, Nielsen TO, van de Rijn M, West RB.

Appl Immunohistochem Mol Morphol. 2012 Oct;20(5):445-50. doi: 10.1097/PAI.0b013e318244ff4b.

PMID:
22495377

Supplemental Content

Loading ...
Support Center